Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha-Lipoic Acid in Symptomatic Diabetic Polyneuropathy
NCT05813496Phase 4Completed
- Sponsor
- EVA Pharma
- Start
- Oct 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of alpha-lipoic acid in diabetic polyneuropathy (DPN), sponsored by EVA Pharma. Primary endpoint: Relative change in Nerve Conduction Studies parameters at 4 weeks. Started Oct 2022; status: completed.
02
Drugs
alpha-lipoic acid
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on NCT05813496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05813496.